Telcon RF Pharmaceutical Decides to Acquire and Cancel KRW 3 Billion of Its Own Convertible Bonds Before Maturity, Reducing Potential Dilution Risk
Telcon RF Pharmaceutical announced on May 27, 2026, that its board resolved to acquire KRW 3 billion (face value) of its 23rd series unregistered unsecured private convertible bonds in an over-the-counter transaction and cancel them entirely.
The acquired bonds are part of the KRW 12 billion CB issued on April 22, 2025. Sellers are SangSangin Savings Bank (KRW 1.75 billion) and SangSangin Plus Savings Bank (KRW 1.25 billion), neither affiliated with the company.
The acquisition cost is approximately KRW 3.119 billion, including principal and interim interest, funded by internal cash. After acquisition, remaining CB face value stands at KRW 9 billion.
The CB conversion price is KRW 1,000 per share, well above the current stock price of KRW 473, making conversion unlikely. However, cancellation reduces potential dilution from future conversion, benefiting existing shareholders.
[AI Comprehensive Analysis]This voluntary early acquisition and cancellation of CBs signals a positive intent to reduce financial burden and protect shareholder value. However, the use of internal cash may constrain short-term financial flexibility. Given the wide gap between conversion price and current share price, the practical impact is likely limited.
KOSDAQ Filing Information
Filing: Report On Major Events (Decision On Acquisition Before Maturity Of Self-Convertible Bonds)